CRIZOTINIB CAP,ORAL
Clinical Criteria Summary
Exclusion Criteria
- History of interstitial fibrosis or interstitial lung disease
- History of congenital long QT syndrome
- Unmanageable drug-drug interactions
- Inadequate bone marrow function (Absolute Neutrophil Count < 1000/mm3, platelets < 50,000/mm3, hemoglobin < 8g/dL), unless due to marrow involvement
- Pregnancy
- Lactating
Inclusion Criteria
- Care provided by a VA/VA Community Care hematology or oncology provider
- Goals of care and role of Palliative Care consult discussed and documented
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Relapsed or refractory systemic Anaplastic Lymphoma Kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
- Unresectable, recurrent or refractory ALK-positive inflammatory myofibroblastic tumor (IMT)
Reproductive Health & Pregnancy Management
- Pregnancy must be excluded prior to receiving crizotinib for patients who can become pregnant
- Counseling on potential risks vs benefits of treatment and use of effective contraception during therapy and for 45 days after stopping treatment for patients who can become pregnant
- Counseling on potential risks vs benefits of treatment and use of effective contraception during therapy and for 90 days after stopping treatment for patients with partners who can become pregnant